Pyc Therapeutics Ltd has released a press release.
Shareholder Update - Forward View 2020 Milestones
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- June 2020 Quarterly Activity Report and Cashflow
- Successful Dose Response & Toxicity Studies in Lead Program
- S&P DJI Announces June 2020 Quarterly Rebalance
- March 2020 Quarterly Activities and Cash Flow Report
- Successful Efficacy Result on Path to First in Human Studies
Later from PYC Therapeutics
- Executive re-structure across global operations
- Appendix 4E Preliminary Final Report
- Creation of Novel Gene Therapy Delivery Technology
- Second Potential Blockbuster Drug Added to PYCs Pipeline
- PYCs Lead Drug Effective in Patient Derived Models Tested
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics